Mereo BioPharma Group (MREO) Competitors $3.58 +0.09 (+2.58%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MREO vs. HRMY, IRON, EVO, CNTA, TARS, RXRX, NRIX, XNCR, GLPG, and IMCRShould you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Harmony Biosciences (HRMY), Disc Medicine (IRON), Evotec (EVO), Centessa Pharmaceuticals (CNTA), Tarsus Pharmaceuticals (TARS), Recursion Pharmaceuticals (RXRX), Nurix Therapeutics (NRIX), Xencor (XNCR), Galapagos (GLPG), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. Mereo BioPharma Group vs. Harmony Biosciences Disc Medicine Evotec Centessa Pharmaceuticals Tarsus Pharmaceuticals Recursion Pharmaceuticals Nurix Therapeutics Xencor Galapagos Immunocore Mereo BioPharma Group (NASDAQ:MREO) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, community ranking, dividends, valuation and analyst recommendations. Do institutionals & insiders have more ownership in MREO or HRMY? 62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 4.1% of Mereo BioPharma Group shares are owned by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate MREO or HRMY? Mereo BioPharma Group currently has a consensus price target of $7.50, indicating a potential upside of 109.50%. Harmony Biosciences has a consensus price target of $47.00, indicating a potential upside of 43.34%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than Harmony Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Harmony Biosciences 2 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.56 Does the MarketBeat Community prefer MREO or HRMY? Harmony Biosciences received 9 more outperform votes than Mereo BioPharma Group when rated by MarketBeat users. However, 77.19% of users gave Mereo BioPharma Group an outperform vote while only 66.25% of users gave Harmony Biosciences an outperform vote. CompanyUnderperformOutperformMereo BioPharma GroupOutperform Votes4477.19% Underperform Votes1322.81% Harmony BiosciencesOutperform Votes5366.25% Underperform Votes2733.75% Which has better valuation & earnings, MREO or HRMY? Harmony Biosciences has higher revenue and earnings than Mereo BioPharma Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMereo BioPharma Group$10M50.21-$29.47MN/AN/AHarmony Biosciences$582.02M3.21$128.85M$2.1115.54 Is MREO or HRMY more profitable? Harmony Biosciences has a net margin of 17.98% compared to Mereo BioPharma Group's net margin of 0.00%. Harmony Biosciences' return on equity of 23.16% beat Mereo BioPharma Group's return on equity.Company Net Margins Return on Equity Return on Assets Mereo BioPharma GroupN/A N/A N/A Harmony Biosciences 17.98%23.16%14.24% Does the media prefer MREO or HRMY? In the previous week, Mereo BioPharma Group had 5 more articles in the media than Harmony Biosciences. MarketBeat recorded 9 mentions for Mereo BioPharma Group and 4 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 0.57 beat Mereo BioPharma Group's score of 0.15 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Harmony Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryHarmony Biosciences beats Mereo BioPharma Group on 10 of the 16 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get Mereo BioPharma Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MREO vs. The Competition Export to ExcelMetricMereo BioPharma GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$502.13M$6.45B$5.03B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E RatioN/A10.78135.4117.82Price / Sales50.21243.751,160.9774.56Price / CashN/A22.1633.5332.53Price / Book9.945.474.674.68Net Income-$29.47M$153.61M$119.07M$226.08M7 Day Performance-6.28%-2.00%-1.83%-1.04%1 Month Performance-20.97%-7.46%-3.60%1.04%1 Year Performance57.02%31.82%31.66%26.28% Mereo BioPharma Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MREOMereo BioPharma Group2.9665 of 5 stars$3.58+2.6%$7.50+109.5%+63.5%$502.13M$10M0.0040Analyst RevisionNews CoverageHRMYHarmony Biosciences4.7919 of 5 stars$32.79+1.0%$47.00+43.3%+18.1%$1.87B$582.02M15.54200IRONDisc Medicine3.1676 of 5 stars$61.50-1.7%$85.80+39.5%+22.4%$1.83BN/A0.0078Insider TradeAnalyst RevisionEVOEvotec1.9292 of 5 stars$5.14-3.0%$5.93+15.4%-49.7%$1.82B$845.74M0.005,061CNTACentessa Pharmaceuticals4.06 of 5 stars$15.79-5.7%$25.83+63.6%+144.7%$1.79B$6.85M0.0072TARSTarsus Pharmaceuticals1.8691 of 5 stars$45.30-2.7%$54.20+19.6%+166.2%$1.73B$17.45M-12.2350Analyst RevisionRXRXRecursion Pharmaceuticals1.9971 of 5 stars$6.01-0.5%$9.25+53.9%-12.0%$1.72B$44.58M0.00400Analyst ForecastOptions VolumeNRIXNurix Therapeutics2.7301 of 5 stars$23.75+4.9%$29.40+23.8%+247.8%$1.68B$76.99M0.00300XNCRXencor3.5491 of 5 stars$23.72+0.4%$35.75+50.7%+19.3%$1.66B$168.34M-7.41280GLPGGalapagos1.2816 of 5 stars$25.12-2.0%$30.75+22.4%-31.4%$1.66B$259.40M0.001,123Analyst DowngradeShort Interest ↓News CoverageGap DownIMCRImmunocore2.9958 of 5 stars$32.42-0.4%$69.18+113.4%-28.7%$1.62B$249.43M0.00497Positive News Related Companies and Tools Related Companies HRMY Competitors IRON Competitors EVO Competitors CNTA Competitors TARS Competitors RXRX Competitors NRIX Competitors XNCR Competitors GLPG Competitors IMCR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MREO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MREO Stock Alerts